# Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion

> **NCT04664725** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Prostate Cancer Patients

## Interventions

- **DRUG:** Repaglinide, Bupropion and SHR3680

## Key facts

- **NCT ID:** NCT04664725
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-01
- **Primary completion:** 2021-01
- **Final completion:** 2021-05
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2020-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04664725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04664725, "Drug-drug Interaction of SHR3680 With Repaglinide and Bupropion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04664725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*